Benjamin F. Edwards & Company, Inc. Crispr Therapeutics Ag Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 34,081 shares of CRSP stock, worth $1.53 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
34,081
Previous 663
5040.42%
Holding current value
$1.53 Million
Previous $45,000
3988.89%
% of portfolio
0.03%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CRSP
# of Institutions
523Shares Held
58MCall Options Held
1.73MPut Options Held
1.84M-
Capital International Investors Los Angeles, CA7.87MShares$353 Million0.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.78MShares$349 Million3.82% of portfolio
-
Nikko Asset Management Americas, Inc.3.15MShares$142 Million1.99% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.15MShares$142 Million0.13% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$125 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.5B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....